Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure

Pharmacological Reports

Volumn 64, Issue 6, 2012, Pages 1466-1475

  Krysiak, Robert ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Angiotensin converting enzyme inhibitors; Coronary artery disease; Monocytes; Proinflammatory cytokines; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CYTOKINE; ENALAPRIL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 1BETA; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; PERINDOPRIL; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; CYTOKINE RELEASE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPOTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MORNING DOSAGE; MUSCLE HYPOTONIA; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874015633     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70944-1     Document Type: Article

References (27)

1. Abuissa H, O'Keefe J Jr: The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab, 2008, 10, 1157-1166.
2. Campbell DJ: A review of perindopril in the reduction of cardiovascular events. Vasc Health Risk Manag, 2006, 2, 117-124.
3. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet, 2006, 368, 581-558.
4. Dendorfer A, Dominiak P, Schunkert H: ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol, 2005, 170, 407-442.
5. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362, 782-788.
6. Holecki M, Szewieczek J, Chudek J: Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure - are they important for doctors? Pharmacol Rep, 2011, 63, 740-751.
7. Kher N, Marsh JD: Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost, 2004, 30, 665-672. (Pubitemid 40041602)
8. Kothari SA, Le MK, Gandhi PJ: Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. J Thromb Thrombolysis, 2003, 15, 217-225. (Pubitemid 38213192)
9. Krysiak R, Gdula-Dymek A, Okopień B: Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol, 2011, 107, 1010-1018.
10. Krysiak R, Okopień B: Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure. Pharmacol Rep, 2011, 63, 1151-1161.
11. Krysiak R, Okopień B: Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients. Pharmacol Rep, 2011, 63, 95-101.
12. Krysiak R, Okopień B: Pleiotropic effects of angiotensin- converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep, 2008, 60, 514-523.
13. Krysiak R, Okopień B: The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis. J Clin Endocrinol Metab, 2011, 96, 2206-2215.
14. Krysiak R, Sierant M, Marek B, Bienek R, Okopień B: The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease. Endokrynol Pol, 2010, 61, 280-287.
15. Krysiak R, Sierant M, Marek B, Okopień B: The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Endokrynol Pol, 2010, 61, 683-690.
16. Krysiak R, Stachura-Kułach A, Okopień B: Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances. Pharmacol Rep, 2010, 62, 120-130.
17. McFarlane SI: Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials. Expert Rev Cardiovasc Ther, 2009, 7, 1363-1371.
18. Naftilan AJ: Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth. Curr Opin Nephrol Hypertens, 1994, 3, 218-227.
19. Neultel JM: Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens, 2004, 18, 599-606.
20. Okopień B, Krysiak R, Haberka, M, Herman ZS: Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol, 2005, 45, 314-320. (Pubitemid 40411286)
21. Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Herman ZS: Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol, 2005, 46, 377-386. (Pubitemid 41262842)
22. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001, 358, 1033-1041.
23. Ridker PM: Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev, 2007, 65, S253-259.
24. Sironi L, Nobili E, Gianella A, Gelosa P, Tremoli E: Antiinflammatory properties of drugs acting on the renin-angiotensin system. Drugs Today, 2005, 41, 609-622. (Pubitemid 41810476)
25. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev, 2006, 86, 515-581.
26. Wilson HM, Barker RN, Erwig LP: Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol, 2009, 7, 234-243.
27. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342, 145-153.